Boston, USA — 29 September – 1 October 2026 , The 5th mRNA Process Development & CMC Summit, hosted by Hanson Wade, has recently concluded successfully.

A premier global conference focused on mRNA and LNP research through to commercial manufacturing, the summit brought together subject‑matter experts from leading pharma and biotech companies including Eli Lilly, Sanofi, BioNTech, Genentech, and etc. Attendees explored critical industry pain points across upstream/downstream processing, analytical development, LNP delivery, manufacturing scale‑up, circRNA, saRNA and CDMO supply chains to resolve bottlenecks for next‑generation mRNA therapeutics.

As an Innovation Partner for this year’s summit, Enorna held face‑to‑face technical and business discussions with international industry peers and prospective partners. Dr. Bang Bai, the company’s Global Business Development Director, delivered a keynote speech on site. In his talk, he laid out Enorna’s platform strengths and real‑world project track record covering targeted LNP delivery, end‑to‑end mRNA‑LNP CMC development, large‑scale GMP manufacturing and global clinical translation. His presentation showcased China‑based innovation and industry insights within the global mRNA/LNP community.

LNPs as “Guided Delivery Missiles” – Opening New Frontiers for mRNA Therapeutics

Dr. Bang Bai presented his keynote titled Advancing mRNA Therapeutics with Targeted LNP Delivery: From Platform Innovation to Clinical Translation.

Centered on the mRNA‑LNP 2.0 era, Dr. Bai illustrated how LNPs — acting as precision‑guided delivery missiles — enable breakthrough modalities such as personalized cancer vaccines, in‑vivo gene editing and in‑vivo CAR‑T therapies. He highlighted critical hurdles for the wider sector when scaling next‑generation targeted LNPs, establishing robust CMC frameworks and executing global clinical programs, while sharing practical, field‑tested solutions derived from Enorna’s hands‑on project experience.

Key Keynote Takeaways

1. mRNA‑LNP enters the 2.0 era, expanding the boundaries of nucleic‑acid therapeutics

mRNA technology has evolved well beyond conventional prophylactic vaccines. It unlocks huge therapeutic potential across personalized cancer vaccines (PCV), in‑vivo gene editing, in‑vivo CAR‑T and in‑vivo T‑cell engager (TCE) programs. As the make‑or‑break delivery vehicle, the LNP delivery system fulfills three core missions: protecting nucleic acids, targeting tissues and cells, and mediating intracellular release and translation.

As novel mRNA modalities advance toward clinical trials, the industry faces stringent CMC challenges around LNP targeting specificity, high‑concentration encapsulation, batch‑to‑batch consistency, and long‑term storage stability.

2. Proprietary lipid and targeted LNP platforms, Enorna overcomes key barriers to industrialization

Drawing on years of process R&D and manufacturing expertise, Enorna has built a fully‑validated in‑house platform for novel lipids and targeted LNP delivery, resolving major roadblocks for mRNA industrialization.

• The team has completed development and scale‑up of 25+ novel cationic lipids, consistently achieving PDI < 0.2 (average 0.1), encapsulation efficiency (EE) >90% (up to 99% for certain cases).

• Proprietary antibody‑conjugated targeted LNP (tLNP) platform delivers >95% conjugation efficiency and >80% in vivo targeting efficiency, with drug products maintaining at least 6‑month long‑term stability, strongly supporting the development of extrahepatic‑targeted programs such as in vivo CAR‑T.

• Overcome technical hurdles for high‑concentration mRNA‑LNP encapsulation, meeting high‑dose administration requirements for projects such as gene editing.

• Equipped with a full suite of equipment from small‑scale to large‑scale. Small‑batch personalized cancer vaccines (PCV) can be delivered in as fast as 6‑7 weeks, satisfying diverse requirements for, NHP studies, IIT studies and clinical GMP manufacturing.

Recommended reading: In Vivo CAR Therapy Solutions-Enorna Biotechnology

3. IIT‑driven clinical strategy, Enorna accelerates pipelines for global Biotechs

Backed by well‑established IIT clinical advancement system and global service capabilities, Enorna helps global partners move nucleic‑acid drug candidates forward rapidly. For diverse innovative mRNA applications including gene editing, protein replacement, cancer vaccines and immunotherapies, Enorna provides end‑to‑end support covering early‑stage CMC development, sample preparation, IIT clinical initiation, and international IND filings.

Leveraging its Global IIT Alliance, Enorna has helped numerous projects rapidly achieve clinical translation, shorten R&D timelines and navigate global regulatory pathways, substantially accelerating global roll‑out and commercialization of innovative nucleic‑acid drugs.

4. Delivering customized end‑to‑end CMC support for multiple therapeutic modalities

Enorna addresses differentiated CMC pain points including LNP encapsulation efficiency, high‑concentration encapsulation, impurity control, targeted conjugation and small‑batch personalized vaccine manufacturing, for diverse mRNA use‑cases such as lyophilized vaccines, gene editing, personalized cancer vaccines (PCV), in vivo CAR‑T, in vivo TCE and protein replacement therapies. To date, Enorna has supported dozens of collaborative projects advancing to IIT and IND stages, with multiple pipelines entering global clinical development.

Addressing Global Market Needs: Unlocking Enorna’s core value as a CRDMO

At the summit booth, Enorna demonstrated its platform strengths in end‑to‑end mRNA‑LNP process development, analytical development and large-scale GMP manufacturing via well-established process and real‑world project cases, allowing attendees to experience Enorna’s profound technical accumulation and hands‑on project track record as a one‑stop nucleic‑acid drug CMC partner.

Considering differing national industrial foundations, regulatory frameworks and differentiated development priorities for mRNA projects, Enorna delivers customized collaboration solutions, ranging from process route design and regulatory submission strategy to clinical translation support, to fully meet development demands of global partners.

The summit offered Enorna a valuable chance to expand its global industry network and build fresh momentum for international business expansion.

The summit has concluded and on‑site conversations have come to an end, yet exploration continues.

As a one‑stop mRNA CRDMO centered on LNP‑delivery technology, Enorna will keep refining its targeted LNP platform capabilities. Working alongside global peers, Enorna will tackle CMC and clinical‑translation challenges for nucleic‑acid drugs, and accelerate translation of nucleic‑acid innovations to benefit patients worldwide.